NCT03605433

Surgical Revascularization Outcomes After Oral Anticoagulation or Antiplatelets

Surgical Coronary Revascularization Outcomes After Oral Anticoagulation or Antiplatelet Strategies

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Unidade Local de Saúde de Coimbra, EPE · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The primary purpose of this study is to evaluate whether treatment with oral anticoagulation or oral anticoagulation and aspirin is better than aspirin alone in cardiovascular outcomes and saphenous graft patency in patients submitted to coronary artery bypass graft.

Conditions

• Coronary Artery Disease
• Saphenous Vein Graft Patency

Interventions

Type	Name	Description
DRUG	Rivaroxaban	Rivaroxaban 2.5 mg or Rivaroxaban 20 mg or no oral anticoagulation

Timeline

• Start date: 2018-12-01
• Primary completion: 2019-12-31
• Completion: 2020-12-31
• First posted: 2018-07-30
• Last updated: 2018-07-30

Locations

1 site across 1 country: Portugal